- The three companies will work to accelerate development of
automated insulin delivery system for people living with
diabetes
- System is being designed to include Abbott's FreeStyle
Libre® 3 sensor, CamDiab's CamAPS FX algorithm, and
Ypsomed's mylife™ YpsoPump®
- Partnership demonstrates the companies' collective desire to
drive integrated solutions to help people with diabetes better
manage their condition and improve health outcomes
BARCELONA, Spain, April 27, 2022 /PRNewswire/ -- Abbott (NYSE:
ABT), CamDiab and Ypsomed today announced that they are partnering
to develop and commercialize an integrated automated insulin
delivery (AID) system to help lessen the burden of round-the-clock
diabetes management for people with diabetes. The initial focus of
the partnership will be in European countries.
The new integrated AID system is being designed to connect
Abbott's FreeStyle Libre® 3 sensor, the world's
smallest1 and most accurate2,3 continuous
glucose monitoring sensor with readings every minute, to CamDiab's
CamAPS FX mobile app, which connects with Ypsomed's mylife™
YpsoPump® – creating a smart, automated process to
deliver insulin based on real-time glucose data. The connected,
smart wearable solution is designed to continuously monitor a
person's glucose levels and automatically adjust and deliver the
right amount of insulin at the right time, removing the guesswork
of insulin dosing.
"Our goal is to make diabetes care as easy as possible, which is
why Abbott continues to expand its team of insulin delivery
partners, digital coaching and technology leaders," said
Jared Watkin, senior vice president
of Abbott's diabetes care business. "We want to deliver new
advanced solutions that simplify and make it possible for people to
spend less time thinking about diabetes and more time living."
"Poor glucose control leads to an increased risk of diabetes
complications such as blindness, and heart and kidney disease. We
want to help people with diabetes better manage their glucose
through advanced technology. Our CamAPS FX, already approved in
Europe, is a highly adaptive
algorithm that when integrated with Abbott's sensor is being
designed to communicate with Ypsomed's insulin pump to provide the
optimal insulin dose, lifting the burden of managing a condition
that is relentlessly unpredictable day and night," said
Roman Hovorka, director of CamDiab
Ltd.
"We are convinced that major challenges of society can only be
addressed through partnerships. We are therefore proud to expand
our partners and connectivity to offer more freedom of choice in
managing diabetes. When combined our
mylife™ YpsoPump® with the FreeStyle Libre 3
system and CamAPS FX advanced adaptive hybrid closed-loop app, we
will be able to deliver an additional compact and lightweight AID
system that is discreet and simple to use," said
Simon Michel, chief executive
officer of Ypsomed.
The companies intend to complete development by end of 2022 with
commercial availability expected thereafter.
About Abbott
Abbott is a global healthcare leader that
helps people live more fully at all stages of life. Our portfolio
of life-changing technologies spans the spectrum of healthcare,
with leading businesses and products in diagnostics, medical
devices, nutritionals and branded generic medicines. Our 113,000
colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at
www.linkedin.com/company/abbott-/, on Facebook at
www.facebook.com/Abbott and on Twitter @AbbottNews.
About CamDiab
CamDiab Ltd is a digital health and
personalized medicine company focused on the design, development,
and commercialization of its world leading, interoperable CamAPS FX
closed loop app. The CamAPS FX is designed to use adaptive,
self-learning control algorithm, linked to a compatible continuous
glucose monitoring device and a compatible insulin pump, to
autonomously compute and direct insulin delivery to maintain tight
glycaemic control. Since its founding in 2019, its mission has been
to help people with type 1 diabetes and their families live better
lives. For further information, visit www.camdiab.com or follow
CamDiab Ltd and its products on Facebook, LinkedIn, and Twitter
@CamAPS_FX.
About Ypsomed
Ypsomed is the leading developer and
manufacturer of injection and infusion systems for self-medication
and a renowned diabetes specialist with over 35 years' experience.
As a leader in innovation and technology, it is a preferred partner
of pharmaceutical and biotech companies for pens, autoinjectors,
pump systems and software solutions for administering liquid
medications. Ypsomed presents and markets its product portfolios
under the umbrella brands mylife™ Diabetescare directly to
patients or via pharmacies and hospitals as well as under
YDS™ Ypsomed Delivery Systems in business-to-business
operations with pharmaceutical companies. The company is
headquartered in Burgdorf, Switzerland, and has a global network of
production facilities, subsidiaries and distribution partners
employing a staff of around 1,900 employees worldwide.
www.ypsomed.com
1 Among patient-applied sensors. Data on file, Abbott Diabetes
Care.
2 FreeStyle Libre 3 User Manual.
3 Data on file. Abbott Diabetes Care, Inc. Comparison based on
publicly available information.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/abbott-camdiab-and-ypsomed-unveil-new-automated-insulin-delivery-partnership-for-people-with-diabetes-301533788.html
SOURCE Abbott